alexa Clinical Trials In Cystic Fibrosis Patients; Does Tachycardia Matter?: A Case Report | 72952
ISSN: 2155-9627

Journal of Clinical Research & Bioethics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Advanced Clinical Research and Clinical Trials

Khalid Abou Farha
Celerion, Clinical Pharmacology Research Centre, UK
Keynote: J Clin Res Bioeth
DOI: 10.4172/2155-9627-C1-001
Abstract
Background: Clinical trials in cystic fibrosis (CF) patients might include post-B2 agonist bronchodilator (e.g. Salbutamol) evaluation of pulmonary functions. Sinus and SVT tachycardia have known dose-related side effects of inhaled salbutamol. A relationship between inhaled beta 2 agonists and increased risk of myocardial ischemia (MI) and infarction has been reported. Under normal breathing conditions, CF patients might show mild tachycardia compared to healthy subjects. Nevertheless, the impact of B2 agonists on the CF- associated tachycardia is often an ignored safety parameter in CF clinical trials. Here, we demonstrate a case of post-salbutamol clinically significant tachycardia associated with ECG features of MI in a CF patient. Case Report: A 21 year old CF female patient has been included in a clinical trial evaluating a new medication for the treatment of CF. Medical history, physical examination, vital signs and laboratory investigations showed no clinically relevant findings. A 12- leads ECG recording showed a sinus rhythm with a heart rate (HR) of 90 bpm. An inhalation dose of 400ug salbutamol has been administered to perform post bronchodilator (PBD) pulmonary function tests and collect spontaneously expectorated sputum. The patient’s cardiac electrical activity was monitored (by means of telemetry) before (baseline, BL) and after salbutamol administration. A pre-bronchodilator (Pre-BD) telemetric recording showed episodes of asymptomatic tachycardia with fluctuating resting heart rate between 79 to 117 bpm, without ECG signs of myocardial ischemia. At 45- 60 minutes after salbutamol administration, the telemetric recordings showed sinus tachycardia with resting HR fluctuating between 97 to 141 bpm and ECG manifestation of tachycardia-induced myocardial ischemia (Figures 1 and 2). 3 to 4 hours post salbutamol the HR returned to BL, and the patient has been discharged after ensuring her safety. Thyroid function tests have been performed to verify the aetiology of the tachycardia. These demonstrated normal results. Re-challenge tests have been performed on other visit. These confirmed the salbutamol associated cardiac effect. Discussion & Conclusion: B2 agonist should be administered with caution to tachycardic CF patients. This may imply salbutamol dose adjustment and requires monitoring with cardiac telemetry. This might avoid unwanted cardiovascular adverse effects such as MI. This line of reasoning is substantiated by the increased likelihood of CF- associated cardiac CFTR chloride channel abnormality that results in deficient CFTR- induced cardiac ischaemic preconditioning and therefore increase the risk for ischemic heart disease in CF patients, particularly in the older age group with pre-existing decreased cardiac reserve.
Biography

Khalid Abou Farha is medical director and clinical pharmacologist of Celeron he brings 15 years of clinical research experience to this role, spanning a wide range of therapeutic areas, with a particular focus in oncology, vaccines, cancer immunotherapy, personalized medicine and autoimmune disorders. He has extensive experience in building and managing global teams, leading the development of Clinical Research drugs and biologics.

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

kactakapaniyor.com

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

Taktube

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

porn sex

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

Gaziantep Escort

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

sikiş

[email protected]

1-702-714-7001Extn: 9037

instafollowers

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

mp3 indir

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

putlockers

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

seks

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7